Simcere Pharmaceutical Group Limited
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×0.70 | 3 |
Strategy profile
Based on 5 disclosed transactions, Simcere Pharmaceutical Group Limited concentrates its licensing activity in Oncology, Immunology, and Dermatology. Simcere Pharmaceutical Group Limited pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $209M. Most recent activity: 2023.
Pipeline coverage & gaps
Simcere Pharmaceutical Group Limited has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 5 | $16M | $209M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2023 | Rademikibart | Connect Biopharma | atopic dermatitis, asthma | phase_3 | $21M | $146M |
| 2023 | rademikibart | Connect Biopharma Holdings Limited | atopic dermatitis | phase_2 | $21M | $144M |
| 2021 | paxalisib | Kazia Therapeutics Limited | glioblastoma | phase_2 | $11M | $292M |
| 2021 | Paxalisib (GDC-0084) | Kazia Therapeutics | glioblastoma (GBM) | phase_2 | $11M | $292M |
| 2020 | trilaciclib | G1 Therapeutics | solid_tumor | phase_2 | $14M | $170M |
How this is computed
For each Simcere Pharmaceutical Group Limited deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 0.362, clamped to [0.7, 1.5].